Results 31 to 40 of about 1,459,292 (318)

Molecular monitoring of HIV-1 drug resistance in Ifakara HIV-1 Cohort, Tanzania [PDF]

, 2013
HIV-1 resistance is one of the problems affecting success of antiretroviral therapy programmes worldwide. Many studies on efficacy of ART programmes, specifically on drug resistance, have been conducted in developed countries but not in developing ...
Masimba, Pax Jessey
core   +1 more source

Molecular Basis for Drug Resistance in HIV-1 Protease

Viruses, 2010
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the ...
Celia A. Schiffer, Kelly Thayer, Ellen A. Nalivaika, Ayşegül Özen, Moses M. Prabu-Jeyabalan, Madhavi N.L. Nalam, Nancy M. King, Rajintha M. Bandaranayake, Jennifer F. Murzycki, Seema Mittal, Madhavi Kolli, Yufeng Cai, Akbar Ali   +12 more
doaj   +1 more source

A folding inhibitor of the HIV‐1 protease [PDF]

Proteins: Structure, Function, and Bioinformatics, 2005
AbstractBecause the human immunodeficiency virus type 1 protease (HIV‐1‐PR) is an essential enzyme in the viral life cycle, its inhibition can control AIDS. The folding of single‐domain proteins, like each of the monomers forming the HIV‐1‐PR homodimer, is controlled by local elementary structures (LES, folding units stabilized by strongly interacting,
R. A. Broglia, D. Provasi, F. Vasile, G. Ottolina, R. Longhi, G. Tiana   +5 more
openaire   +4 more sources

HIV Protease Inhibitors Disrupt Lipid Metabolism by Activating Endoplasmic Reticulum Stress and Inhibiting Autophagy Activity in Adipocytes

PLoS ONE, 2013
Background HIV protease inhibitors (PI) are core components of Highly Active Antiretroviral Therapy (HAART), the most effective treatment for HIV infection currently available.
B. Zha, Xiao-Shan Wan, Xiaoxuan Zhang, Wei-bin Zha, Jun Zhou, M. Wabitsch, Guang-Ji Wang, V. Lyall, P. Hylemon, Huiping Zhou   +9 more
semanticscholar   +1 more source

Personalizing HIV therapy, mission impossible? [PDF]

, 2013
Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core   +1 more source

HIV-2 Protease resistance defined in yeast cells

Retrovirology, 2006
Background Inhibitors of the HIV-1 Protease currently used in therapeutic protocols, have been found to inhibit, although at higher concentrations, the HIV-2 encoded enzyme homologue.
Raoult Didier, Audoly Gilles, M'Barek Najoua, Gluschankof Pablo   +3 more
doaj   +1 more source

Novel wild type and mutate HIV-1 protease inhibitors containing heteroaryl carboxamides in P2: Synthesis, biological evaluations and in silico ADME prediction

Results in Chemistry, 2023
The Virus HIV-1 infection still represents a serious disease even if actually it is transformed in chronic pathology. Considering the crucial role of the enzyme Protease in life cycle of HIV many efforts have been made in the research of new organic ...
Maria Francesca Armentano, Paolo Lupattelli, Faustino Bisaccia, Rosarita D'Orsi, Rocchina Miglionico, Ilaria Nigro, Alessandro Santarsiere, Federico Berti, Maria Funicello, Lucia Chiummiento   +9 more
doaj   +1 more source

Class of antiretroviral drugs and the risk of myocardial infarction [PDF]

, 2007
BACKGROUND:We have previously demonstrated an association between combination antiretroviral therapy and the risk of myocardial infarction. It is not clear whether this association differs according to the class of antiretroviral drugs.
El-Sadr, W, De Wit, S, Phillips, Andrew, Friis-Moller, Nina, Weber, R, Reiss, Peter, Lundgren, JD, O. Kirk, W. M. El Sadr, Monforte, AD, R. Thiébaut, El-Sadr, Wafaa, R. Weber, Friis-Moller, N, N. Friis Møller, Law, MG, Lundgren, Jens D., Kirk, O, Thiebaut, Rodolphe, Fontas, E, Friis-Møller, Nina, De Wit, Stephane, Sabin, Caroline, P. Reiss, S. De Wit, A. N. Phillips, Sabin, CA, d'Arminio Monforte, Antonella, Law, Matthew G., Reiss, P, E. Fontas, Sabin, Caroline A., Lundgren, Jens D, DAD Study Grp, Monforte, Antonella d'Arminio, Phillips, Andrew N., J. D. Lundgren, Phillips, A, Fontas, Eric, M. G. Law, Weber, Rainer, C. A. Sabin, Kirk, Ole, A. d’Arminio Monforte, Law, Matthew   +44 more
core   +1 more source

Noninvasive High-Throughput Single-Cell Analysis of HIV Protease Activity Using Ratiometric Flow Cytometry

Sensors, 2013
To effectively fight against the human immunodeficiency virus infection/ acquired immunodeficiency syndrome (HIV/AIDS) epidemic, ongoing development of novel HIV protease inhibitors is required.
Rok Gaber, Andreja Majerle, Roman Jerala, Mojca Benčina   +3 more
doaj   +1 more source

Insights Into the Broad Cellular Effects of Nelfinavir and the HIV Protease Inhibitors Supporting Their Role in Cancer Treatment and Prevention

Current Opinion in Oncology, 2013
Purpose of review The development of HIV protease inhibitors more than two decades ago heralded a new era in HIV care, changing the infection from universally fatal to chronic but controllable.
S. Gantt, C. Casper, R. Ambinder
semanticscholar   +1 more source